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The aim of the present study was to assess the bioequivalence of two cephalexin tablet formulations 
available in the Brazilian market (product A as reference formulation and product B as test 
formulation). Dissolution efficiency (DE%) was calculated for both formulations to evaluate their in 
vitro biopharmaceutical features. The oral bioequivalence study was performed in twenty-four healthy 
volunteers in a crossover design. Single oral dose (tablet containing 500 mg of cephalexin) of each 
product was administered with two weeks of washout period. Urinary concentrations of cephalexin 
were measured by high-performance liquid chromatography (HPLC) method and pharmacokinetics 
parameters were estimated by urinary excretion data. The bioequivalence was determined by the following 
parameters: the cumulative amount of cephalexin excreted in the urine, the total amount of cephalexin 
excreted in the urine and the maximum urinary excretion rate of cephalexin. DE values of immediate-
release cephalexin tablets (500 mg) were 68.69±4.18% for product A and 71.03±6.63% for product B. 
Regarding the dissolution test of the two brands (A and B) analysed, both were in compliance with the 
official pharmacopeial specifications, since the dissolution of both formulations was superior to 80% 
of the amount declared in the label after 45 minutes of test (A=92.09%±1.84; B=92.84%±1.08). The 
results obtained indicated that the products A and B are pharmaceutical equivalents. Confidence intervals 
for the pharmacokinetic parameters were in compliance with the international standards, indicating that 
products A and B can be considered bioequivalents and, therefore, interchangeable.
Uniterms: Tablets/formulations/bioequivalence study. Cephalexin/dissolution efficiency.
O objetivo do presente estudo foi avaliar a bioequivalência de duas formulações de cefalexina disponíveis 
no mercado brasileiro (produto A como formulação referência e produto B como formulação teste). A 
eficiência de dissolução (DE%) foi calculada para ambas as formulações para avaliar suas características 
biofarmacêuticas. O estudo de bioequivalência oral foi realizado em vinte e quatro voluntários sadios 
utilizando um desenho cruzado. Uma dose oral única (comprimido contendo 500 mg de cefalexina) de 
cada produto foi administrada com um período de washout de duas semanas. Concentrações urinárias 
de cefalexina foram mensuradas por método de cromatografia líquida de alta eficiência (CLAE) e os 
parâmetros farmacocinéticos foram estimados por dados de excreção urinária. A bioequivalência foi 
determinada pelos seguintes parâmetros: quantidade acumulada da cefalexina excretada na urina, 
quantidade total da cefalexina excretada na urina e a taxa de excreção máxima da cefalexina. Os 
valores de DE dos comprimidos de liberação imediata de cefalexina (500 mg) foram 68,69±4,18% para 
o produto A e de 71,03±6,63% para o produto B. Com relação ao teste de dissolução das duas marcas 
analisadas (A e B), ambas apresentaram-se de acordo com as especificações farmacopéicas, uma vez 
que a dissolução de ambas formulações foi superior a 80% da quantidade declarada após 45 minutos de 
teste (A=92,09%±1,84; B=92,84% ±1,08). Os resultados obtidos indicaram que os produtos A e B são 
equivalentes farmacêuticos. Os intervalos de confiança para os parâmetros farmacocinéticos estavam 
de acordo com os padrões internacionais, demonstrando que os produtos A e B podem ser considerados 
bioequivalentes e, portanto, intercambiáveis.
Unitermos: Comprimidos/estudo de bioequivalência. Cefalexina/eficiência de dissolução.
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INTRODUCTION
Cephalexin is a semi-synthetic cephalosporin widely 
used in the treatment of infectious diseases and it is orally 
administered. Blood concentrations of the drug after usual 
therapeutic dose are high enough to produce bactericidal 
effect against most susceptible microorganisms (Ding et 
al., 2011; Mohamed et al., 2011). 
It is rapidly and completely absorbed from the 
gastrointestinal tract via carrier-mediated transport 
system and is eliminated from the organism mainly by 
urinary excretion. In adults with normal renal function, 
following oral administration of a single 250-500 mg 
dose, peak blood concentration can be obtained within 1 
hour. Approximately 70-90% of cephalexin is excreted 
unchanged in urine (Chow et al., 1979; Ding et al., 2011; 
Nightingale, Greene, Quintiliani, 1975).
In Brazilian market, cephalexin is available for oral 
administration in several brand formulations considered 
interchangeable. However, bioequivalence studies of these 
formulations were not yet developed. The substitution of 
a drug product for a similar requires that both products be 
considered pharmaceutically equivalent and bioequivalent. 
The fundamental reason for performing bioequivalence 
testing is to establish that there are no differences in safety 
and efficacy between the brand products, i.e., they are 
therapeutically equivalent (Grass, 1997). 
Large differences between the rate and efficiency of 
absorption may occur when the same drug is administered 
in same dosage forms that might contain different 
excipients or are made through different processes. 
Sometimes, such factors may affect the appearance of the 
drug in plasma (providing different concentrations) or 
urinary excretion curve (Engel et al., 2012; Grass, 1997).
The pharmacokinetic parameters can be calculated 
from the accumulated amount of excreted drug in the urine 
sample in a particular time interval. However, it is necessary 
that a significant amount of the unchanged drug be excreted 
in the urine, that the analytical method be specific for the 
unchanged drug, that the samples be collected with larger 
frequency to determine the excretion profile and that the 
sampling be made until the almost complete elimination of 
the drug (practically seven half-lives). The decline of the 
plasmatic concentration curves and drug urinary excretion 
rate can be described mathematically by the same equation. 
Thus, it is possible to assume that the parameters obtained 
from urinary excretion data reflect the drug absorption 
(Cawello et al., 2013; Shargel, Yu, 1993). 
However, this hypothesis is valid only when 
the requirements mentioned above are attained. Thus, 
the pharmacokinetics parameters and, therefore, the 
bioavailability and bioequivalence can be calculated 
from the urinary excretion data. Moreover, the studies in 
blood serum may be replaced by the use of urinary data 
of the drug due to its low costs and for being less invasive 
(Otoom, Hasan, Najib, 2004; Portolés et al., 2009; Shargel, 
Yu, 1993).
The aim of this study was to evaluate the dissolution 
efficiency (DE%) and bioequivalence of two tablet 
formulations of cephalexin (500 mg) designated as product 
A (reference formulation) and product B (test formulation) 
available in the Brazilian market using urinary data from 
healthy human volunteers. Previously, the products were 
submitted to physical and physicochemical tests and 
HPLC method was developed and validated in order to 
quantify cephalexin in urine samples.
MATERIAL AND METHODS
Tablets
Tablets of cephalexin 500 mg available in the 
Brazilian market were designated as product A (reference 
formulation) and product B (test formulation) and they 
were used in this study.
Dissolution profiles
Dissolution profiles were obtained using Hanson 
Research Corporation Dissolution System in the following 
conditions: apparatus I (basket, 40 mesh), 100 rpm, 900 
mL of distilled water (dissolution medium) maintained 
at 37.0 ± 0.5 °C. Six tablets were analysed in every assay 
and samples were collected at 5, 7, 10, 15, 20, 30, 40, 45, 
50 and 60 min. Cephalexin concentration was determined 
using UV spectrophotometer with a wavelength of 262 
nm. Dissolution efficiency (DE%) was calculated and 
this value represent the area under the dissolution curve 
up to a specified time and it is expressed as a percentage 
of the rectangle area (Cutrignelli et al., 2011; Khan, 1975; 
Nagabhushanam, Rao, Prabhakar, 2011). 
Bioequivalence study
The protocol of the in vivo assay was approved by 
the Ethical Committee of the University Hospital from 
University of São Paulo. Twenty four male and female 
healthy volunteers, age between 21-35 years and weighting 
49-84 kg were selected for the study. Subjects received 
full explanation about the nature and purposes of the 
bioequivalence study. Then, each volunteer was instructed 
to give written informed consent for participation in 
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the study, according to the principles outlined in the 
Declaration of Helsinki. Medical history, physical 
examination and several laboratory tests (complete blood 
count, hematocrit, serum alkaline phosphatase, serum 
glutamate pyruvate transaminase, serum glutamate 
oxalate pyruvate transaminase, creatinine clearance and 
urinalysis) were carried out prior the study. The results of 
these examinations were within the normal limits for all 
volunteers. Each subject was asked about general health 
and known drug allergies. The volunteers were instructed 
to adhere to a standard protocol and to abstain from taking 
any medication one week before and during the study.
The study was conducted in an open, randomized 
two period cross-over design, according to Latin square 
design. All subjects received single dose of cephalexin 
500 mg. Two brands of cephalexin 500 mg in conventional 
tablets were employed: the reference formulation (product 
A) and the test formulation (product B).
The subjects were divided into two groups. In 
the first period of the study, volunteers from one group 
received product A and volunteers from the other group 
received product B. Two weeks later, this procedure was 
repeated by inverting the groups. Each subject fasted 
overnight prior to the experiment, and no food was allowed 
for 4 hours after cephalexin oral administration. The drug 
was administered with 500 mL of water.
Blank urine samples were obtained from each 
volunteer prior to dosing. Quantitative urine collections 
were obtained during each of the following time intervals: 
30, 60, 90, 120, 180, 240, 300, 360, and 420 min. A volume 
of 250 mL of water were administered after each urine 
collection. A standard lunch was ingested by all subjects 
4 hours after dosing. Urine volume and pH were measured 
and an aliquot of each sample was frozen until analysis 
by HPLC.
Cephalexin quantification in human urine
Urinary concentrations of cephalexin were 
determined by a validated high performance liquid 
chromatographic (HPLC) method with UV detection at 
254 nm. The drug was extracted from 500 mL urine using 
300 mg of NaCl, 25 mL of HCl 0.75 N and 3.0 mL of 
acetonitrile. Then, each sample was mixed using a vortex 
stirrer for one minute and centrifuged for 10 min at 2000 
rpm. A volume of 2.5 mL of the supernatant were separated 
and evaporated to dryness under a N2 stream at 37 °C. The 
residue was reconstituted with 500 mL of mobile phase 
and 20 mL were injected into the chromatographic system. 
Chromatography was performed at room temperature 
using a 15.0 cm x 4.6 mm Supelcosil® 5 mm LC18 column 
(SUPELCO) and the mobile phase was constituted by 
0.25 N acetate buffer pH 3.0 (65%) and methanol (35%) 
at a flow-rate of 1 mL.min-1.
Validation was accomplished through determination 
of recovery, linearity, quantification limit, precision, 
accuracy, specificity and stability (ANVISA, 2003; ICH, 
2005).
Bioequivalence evaluation
Since cephalexin is almost 100% excreted 
unchanged in urine, the pharmacokinetic parameters for 
bioequivalence determination were established using 
urinary excretion data. Urine samples were collected at 
various time periods after dosing and were analysed for 
cephalexin. A graph of the cumulative amount of excreted 
drug versus time intervals of collection was obtained. 
Cumulative amount of excreted cephalexin (Duc) was 
determined by adding the amount of drug excreted in each 
time interval to the amount of drug excreted recovered 
in the previous time intervals. The total amount of drug 
recovered from urine after all excretion period was 
designed by Du∞. In this study the Du∞ was obtained from 
the cumulative excretion at 420 min, using the following 
equation (Arancíbia, 1991; Shargel, Yu, 1993):
(Duc)i = Du∞ – [ 1 / e -kDt] [ (Duc)i+1 – (Duc)i ]
where (Duc)i is the cumulative amount of cephalexin 
excreted at a specific time; (Du)i+1 is the cumulative 
amount of cephalexin excreted at the immediately 
following time; k is the constant rate for elimination; and 
Dt is the time interval.
The drug urinary excretion rate (dDu/dt) cannot 
be determined experimentally for any given instant. 
An average urinary excretion rate is then calculated for 
every collection period. The average values of dDu/dt 
were natural logarithmic (ln) transformed and plotted 
against the midpoint time of the collection period 
(tm). The maximum cephalexin urinary excretion rate 
[(dDu/dt)max] and the middle-time (tmmax) to reach 
[(dDu/dt)max] were registered. The elimination constant 
rate (k) was determined by linear regression of the terminal 
phase of the logarithmically transformed “dDu/dt x tm” 
curve. The elimination half-life (t½)b was calculated 
dividing 0.693 for k. 
When all drug has been excreted (t=∞) the fraction 
of dose absorbed after a single oral dose is given by the 
following equation:
F = k . Du∞ / ke D0
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where F is the fraction of dose absorbed; k is the constant 
rate for elimination; ke is the constant rate of renal 
excretion; Du∞ is the total amount of drug recovered after 
excretion and D0 is the drug dose.
However, since elimination of the drug is usually 
and totally effected by renal excretion, ke=k and:
F = Du∞ / D0
Analysis of variance (ANOVA) was performed for 
the values of the following pharmacokinetic parameters: 
cumulative amount of excreted cephalexin (Duc); total 
cumulative amount of cephalexin excreted (Du∞); maximum 
excretion rate of cephalexin [(dDu/dt)max]; middle-time of 
maximum excretion rate of cephalexin (tmmax); excretion 
constant rate of cephalexin (k) and cephalexin elimination 
half-life (t½)b. Factors accounting for the following 
variation sources were considered: sequence, subjects, 
period and treatment. The 90% confidence interval (90% 
CI) for the ratio between the test and the reference [Duc, 
Du∞ and (dDu/dt)max] were calculated. Bioequivalence is 
confirmed if the 90% CI are within 80-125%.
RESULTS AND DISCUSSION
Dissolution profiles and dissolution efficiency 
(DE%)
Figure 1 shows the dissolution profiles of products 
A and B. DE values of immediate-release cephalexin 
tablets (500 mg) were 68.69±4.18% for product A (p=0.23; 
statistically significant difference was considered if 
p≤0.05) and 71.03±6.63% for product B. 
Cephalexin quantification in urine
The chromatograms of urine showed good resolution 
for all analysis and the retentions times of cephalexin 
were about 5 minutes (Figure 2). Calibration curve 
parameters of cephalexin quantification in human urine by 
chromatographic method were: slope of 10872, y-intercept 
of 131442 and correlation coefficient (r²) of 0.9974. 
The proposed method showed 84.85% of recovery, 
linearity between 10 and 500 mg.mL-1, quantification limit 
of 10 mg.mL-1, intra-assay precision between 2.05 and 
6.00%, inter-assay precision between 1.87 and 2.99%, 
intra-assay recovery between 81.12 and 92.36%, and inter-
assay recovery between 80.08 and 88.84%. The samples 
were stable for 120 days at -20 °C and the organic extracts 
were stable after reconstitution with mobile phase for 
48 hours at room temperature.
The proposed method is suitable for cephalexin 
quantification in urine samples, showed good specificity, 
sensitivity, linearity, precision and accuracy, thereby 
enabling its use in bioequivalence assays. 
Bioequivalence study
Table I shows the mean of cumulative amount of 
cephalexin excreted in urine after oral administration of 
products A and B (immediate-release tablets) to 24 healthy 
FIGURE 1 - Dissolution profiles of immediate-release 
cephalexin tablets (500 mg), A and B products. The figure 
represents the dissolution percentages (arithmetic mean) and 
the standard deviations (n=6)
FIGURE 2 - Chromatogram of blank human urine (1), blank 
human urine with cephalexin 25.0 µg.ml-1 (2), 50.0 µg.mL-1 (3) 
and 100.0 µg.mL-1 (4).
Dissolution efficiency and bioequivalence study using urine data from healthy volunteers 387
volunteers. Mean of cumulative amount of cephalexin 
excreted (Duc), mean of total amount of cephalexin 
excreted (Du∞) and mean of urinary recovery percentage 
of cephalexin in two formulations (A and B) are shown 
in Table II. Very similar mean cumulative amount of 
cephalexin excreted x time profiles were observed for 
products A and B after oral administration (Figure 3). 
Table  I I I  summarizes  the  mean values  of 
pharmacokinetic parameters of both products (A and B) 
after oral administration of cephalexin immediate release 
tablets to 24 healthy volunteers. Urinary excretion rates 
of cephalexin (dDu/dt) for each product are shown in 
Figure 4.
Analysis of variance (ANOVA) according to a 
cross-over model was performed to ln-transformed data 
of products A and B pharmacokinetic parameters. Results 
are summarized in Table IV. 
Table V reports the 90% confidence interval for the 
ratios of Duc, Du∞ and (dDu/dt)max of products A and B.
The results of the present study indicate that there are 
no statistically significant differences between products A 
TABLE I - Mean of cumulative amount of cephalexin excreted 
(Duc) at each time interval following oral administration of 
immediate-release tablets (A and B products, n=24)
Time 
intervals 
(min)
A B
Duc (mg) % Duc (mg) %
0-30 9.64 1.93 7.68 1.54
30-60 93.21 18.64 93.87 18.77
60-90 207.22 41.44 192.52 38.50
90-120 285.30 57.06 269.20 53.84
120-180 361.64 72.34 356.26 71.25
180-240 393.81 78.76 397.15 79.43
240-300 409.92 81.98 414.13 82.83
300-360 417.59 83.52 423.17 84.63
360-420 422.08 84.42 428.39 85.68
TABLE II - Mean of cumulative amount of cephalexin excreted 
(Duc), mean of total amount of cephalexin excreted (Du∞), 
mean of urinary recovery percentage of cephalexin and fraction 
of absorbed dose (F) after oral administration of immediate-
release tablets (products A and B, n=24). Values represent mean 
± standard deviation
Products A B
Duc (mg) 422.08 ± 55.29 428.39 ± 46.37
Recovery (%) 84.42 ± 11.06 85.68 ± 9.27
Du∞ (mg) 427.18 ± 54.81 434.58 ± 47.58
F (%) 85.44 ± 10.96 86.92 ± 9.52
TABLE III - Mean of pharmacokinetics parameters after oral administration of cephalexin (A and B products, n=24). Values represent 
mean ± standard deviation 
Products (dDu/dt)max 
(mg.min-1)
t m max 
(min)
k 
(min -1)
t (½) b 
(min)
A 4.01±0.59 73.10±23.50 0.0123±0.0019 57.60±8.17
B 4.00±1.02 78.80±22.20 0.0120±0.0020 59.19±8.52
[(dDu/dt)max] = maximum rate of cephalexin excretion; tmmax = middle-time of maximum rate of cephalexin excretion; k = cephalexin 
excretion constant rate and t(1/2)b = cephalexin elimination half-life
FIGURE 3 - Mean of cumulative amount of cephalexin excreted 
in urine (Duc) followed by oral administration of immediate-
release tablets (A and B products, n=24). Bars indicate standard 
deviation. 
and B in the in vitro dissolution studies and the cumulative 
urinary excretion of cephalexin at various time points. No 
statistically significant differences were observed for the 
pharmacokinetic parameters and the urine data indicate 
that both products are bioequivalent.
Drug absorption from a solid dosage form after oral 
administration depends on the release of the drug substance 
from the drug product, the dissolution or solubilization 
of the drug under physiological conditions and, the 
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permeability across the gastrointestinal tract (Dahan, 
West, Amidon, 2009; Dezani et al., 2013a; Dezani et al., 
2013b). Because of the critical nature of the first two of 
these steps, in vitro dissolution may be relevant to predict 
in vivo performance. Based on this general consideration, 
in vitro dissolution tests for immediate-release solid oral 
dosage forms, such as tablets and capsules, are used 
to: assess the lot-to-lot quality of a drug product; guide 
development of new formulations; and ensure continuing 
product quality and performance after certain changes, 
such as changes in the formulation, in the manufacturing 
process, in the site of manufacturing, and in the scale-up 
of the manufacturing process. 
Regarding to the dissolution test of the two brands 
(A and B) analysed, both were in accordance with the 
official pharmacopeial specifications, since the dissolution 
of both formulations was superior to 80% of the amount 
declared in the label after 45 minutes of test (A= 92.09% 
± 1.84; B = 92.84% ± 1.08). In general, these dissolution 
standards are single-point dissolution tests, not profiles. 
However, a further parameter suitable for the evaluation 
of in vitro dissolution was suggested by Khan (1975), who 
introduced the idea of dissolution efficiency (DE%). This 
is defined as the area under the dissolution curve up to a 
certain time t, expressed as a percentage of the rectangle 
area described by 100% dissolution in the same time 
(Khan, 1975; USP, 2010).
The DE% was calculated for both formulations to 
accurately evaluate of their in vitro biopharmaceutical 
features. Statistical analysis (ANOVA) of DE% values 
did not show any significant differences between the 
dissolution profiles for products A and B (p=0.23). The 
concept of Dissolution Efficiency has some advantages 
over the single point dissolution test. The first is that 
summation of drug release data into a single figure enables 
a ready comparison to be made between a large numbers 
of formulations. The second advantage, and probably the 
most important, is that it can be theoretically related to 
FIGURE 4 - Mean of urinary excretion rates (dDu/dt) followed 
by oral administration of cephalexin immediate-release tablets 
(A and B products, n=24).
TABLE IV - Values of p obtained after statistical analysis (ANOVA) of ln-transformed data for the following pharmacokinetic 
parameters: cumulative amount of cephalexin excreted (Duc); total cumulative amount of cephalexin excreted (Du∞); maximum 
rate excretion of cephalexin [(dDu/dt)max]; middle-time of maximum excretion rate of cephalexin (tmmax); cephalexin excretion 
constant rate (k), cephalexin elimination half-life (t(1/2)b)
Sources of variation
p*
Duc Du∞ (dDu/dt)max tmmax k t(1/2)b
Period (1 and 2) 0.0041 0.0051 0.9653 0.2621 0.6007 0.5912
Sequence (I and II) 0.0292 0.0374 0.1390 0.5540 0.6890 0.8003
Subject (n = 24) 0.0201 0.0201 0.0804 0.0810 0.0499 0.0194
Product (A and B) 0.6684 0.6159 0.6895 0.3739 0.4931 0.4299
*statistically significant difference was considered if p≤0,05
TABLE V - Confidence intervals (90%) for the ratio of ln-transformed data of Duc, Du∞ and (dDu/dt)max, after oral administration 
of cephalexin immediate-release tablets (A and B products, n=24)
Pharmacokinetic parameter
Confidence Intervals (%)
Lower Limit Upper Limit
Duc 96.81 105.60
Du∞ 96.99 105.81
(dDu/dt)max 89.89 106.79
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in vivo data. If it is assumed that the absorption of a drug 
depends on its degree of solubilization and on the time this 
solution is in contact with a suitable absorptive region of 
the gastrointestinal tract, it can be seen that the Dissolution 
Efficiency as described is a function of these two variables. 
It seems be more logical and realistic use DE% to compare 
and express in vitro results of several formulations instead 
of taking a single-point from the dissolution tests. 
Thus, no discrepancies between both cephalexin 
brands were found in dissolution tests. However, to 
conclude if these pharmaceutical products are therapeutic 
equivalents, the in vivo bioequivalence studies are needed.
The bioequivalence study using A and B products 
was based on an open randomized two period crossover 
design with twenty-four male and female healthy 
volunteers. Pharmacokinetics parameters used in this 
evaluation were obtained from urinary excretion data of 
cephalexin. According to specification of FDA/USA, the 
evaluation of the bioavailability implies in determination 
of the amount of drug absorbed and in the rate of this 
process (FDA, 2003; USP, 2010). As bioequivalence refers 
to the comparative study of bioavailability of two dosage 
forms or products that contain the same drug in the same 
amount, the pharmacokinetic parameters selected should 
reflect the absorption process (Shargel, Yu, 1993). 
The pharmacokinetic parameters can be calculated 
from the accumulated amount of drug excreted in the 
urine in a certain time interval. However, it is necessary 
that a significant amount of the unchanged drug be 
excreted in the urine, the analytical method be specific 
for the unchanged drug, the samples be collected with 
larger frequency to determine the excretion profile 
and the collection be made until the almost complete 
elimination of the drug (practically seven half-lives). 
The decline of the plasmatic curves and drug urinary 
excretion rate can be described mathematically by the 
same expression, so it is possible to assume that the 
parameters obtained from urinary excretion data reflect 
drug absorption. However, this hypothesis is valid only 
when the requirements mentioned above are attained. In 
that way, the pharmacokinetics parameters, and therefore, 
the bioavailability and bioequivalence, can be calculated 
from the urinary excretion data (Kuchake et al., 2009; 
Otoom, Hasan, Najib, 2004; Shargel, Yu, 1993).
The analytical method developed for cephalexin 
quantification in urine samples showed good specificity, 
sensitivity, linearity, precision and accuracy, enabling its 
use in bioequivalence trials.
Urinary recoveries of cephalexin excreted unchanged 
(Duc) after oral administration for both formulations (A 
= 85.44%; B = 86.92%) indicated that the main route of 
elimination is renal excretion. The results were similar 
to those found by Nakagawa and colleagues (1978) that 
obtained 81.6% of recovery 6 hours after the administration 
of 250 mg cephalexin capsules (Nakagawa et al., 1978). 
Finkelstein and colleagues (1978) reported that 90.6% 
and 89.6% were recovered in the urine 24 hours after the 
administration, respectively, of cephalexin capsules and 
tablets (Finkelstein et al., 1978). Posterior studies found 
recoveries of 92.0% and 95.0% of the administered dose 6 
and 24 hours after drug administration (Martinez-Pacheco 
et al., 1988).
Values obtained for maximum excretion rate 
of cephalexin were very similar for both products 
(A = 4.01 ± 0.59 mg.min-1; B = 4.01 ± 1.02 mg.min-1). 
These results are in agreement with that described by other 
authors (5.0 mg.min-1). Values of tmmax were also similar 
(A = 73.10 ± 23.50 min; B = 78.80 ± 22.20 min). Jung 
and colleagues (1991) obtained tmmax of 75 and 105 min, 
respectively, after the administration of 500 mg cephalexin 
capsules and tablets (Jung et al., 1991).
The elimination half-life is a biological constant that 
characterises the kinetic of the drug. The medium values 
of elimination half-life (t(½)b) for normal individuals 
are in agreement with that described by other authors, 
in the range of 36 to 126 min (Nightingale, Greene, 
Quintiliani, 1975). Mean values of 50 ± 10 min after oral 
administration to normal fasting individuals were reported 
(Chow et al., 1979; Finkelstein et al., 1978; Greene et 
al., 1976). Concomitant administration of food changes 
the elimination half-life to 77 min (Greene, Quintiliani, 
Nightingale, 1975).
The elimination rate constant (k) was determined 
by linear regression of the terminal phase of the 
logarithmically transformed “dDu/dt x tm” curve. The 
elimination rate constant (k) can be represented by the 
sum of the non-biotransformed drug urinary excretion rate 
constant (ku) and the biotransformed drug elimination rate 
constant (km) (Rowland, Tozer, 1995). However, since 
cephalexin does not suffer hepatic biotransformation, 
being completely eliminated by renal excretion, k is equal 
to ku. The results obtained for products A and B were in 
agreement with data described by Chow and colleagues 
(1979) and Finkelstein and colleagues (1978), which 
found k values of 0.015 ± 0.003 min-1 (Chow et al., 1979; 
Finkelstein et al., 1978).
A n a l y s i s  o f  v a r i a n c e  w a s  p e r f o r m e d  o n 
pharmacokinetic parameters after natural logarithmic 
(ln) transformation. Factors related to variation sources 
were considered: sequence, subjects, period and treatment.
A significant subject effect was found for Duc, Du∞, k 
and t(½)b, which indicates that, for these pharmacokinetic 
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parameters, intra-individual variation is greater than inter-
individual variation and it confirms the need of using a 
crossover design for the assay (Jackson, 1994).
Sequence effect was observed for Duc and Du∞. 
This effect could be due to a difference between the 
individuals randomly assigned to the two groups, to an 
unequal carryover effect between the tested products or 
to product-period interaction (Jackson, 1994). United 
States Pharmacopeia (2010) states that this effect occurs 
in 10% of all bioequivalence assays and it can be ignored 
if the assay was performed using single dose in healthy 
volunteers; if the drug is not an endogenous substance; 
if an appropriate washout period among the two phases 
is allowed and if it is in conformity with scientific and 
statistical approaches. All these conditions were fulfilled in 
the present study. According to Orsmby (1994), if there are 
no suspicious facts, as different from zero concentrations 
of the drug at the beginning of the second period of the 
assay, the group effect can be ignored (Orsmby, 1994).
No significant treatment effect was found for any 
of the pharmacokinetic parameters evaluated, which 
indicates that there is no difference between products 
A and B. The 90% confidence intervals for the ratio 
between the test and the reference average of Duc, Du∞ and 
(dDu/dt)max were calculated. Bioequivalence was 
confirmed with the results within the interval 80-125%. 
Period effect was found for Duc and Du∞ but does not 
invalidate the assay (Jackson, 1994). Confidence intervals 
for the pharmacokinetic parameters evaluated were 
according to international standards.
Based on this study, some drugs can be evaluated in 
order to predict absorption through urinary excretion data, 
mainly when non-metabolized substances are studied. Due 
to high invasiveness of bioequivalence/bioavailability 
conventional studies, the prediction of absorption can be 
performed using the methodology proposed in this study, 
as well as pharmacokinetics parameters. Furthermore, 
urinary excretion methodology represents low costs, it is 
less invasive method and its throughput is viable when 
compared to conventional method with blood samples. 
Besides that, the involvement of healthy volunteers should 
be taken in account. The meal control and pre-treatment 
procedures before and during the experiments must be 
responsibility of the researchers as well as the volunteers 
to avoid variation in the methodology. Thus, the conditions 
must be established and standardized to minimize errors 
during the study (Cawello et al., 2013; Otoom, Hasan, 
Najib, 2004; Portolés et al., 2009; Shargel, Yu, 1993). 
The rate and extension of a drug excreted in the 
urine reflect the rate and extent of its absorption process 
(Shargel, Yu, 1993). Thus, it is possible to evaluate 
bioavailability/bioequivalence of two formulations using 
parameters derived from urinary excretion. Several reports 
in the literature indicate that urinary excretion data can 
be used for studies of bioavailability and bioequivalence 
between different medicinal products (Wagenlehner et al., 
2006; Tubic et al., 2006; Otoom, Hasan, Najib, 2004; Shah 
et al., 2002; Pillai et al., 2001) since the graph obtained 
from urinary excretion rate (dXu/dt) versus time (t), result 
in a curve very similar to the curve obtained from plasma 
versus time. Thus, according to Shargel and Yu (1993), the 
plasma concentration-time curve and excretion rate of a 
drug are overlapping. Thus, the parameters for elimination 
of drug in urine reflect those related to its absorption 
(Serra, Storpirtis, Gonçalves, 2011). 
CONCLUSION
Cephalexin is a drug widely used for infectious 
diseases. However, bioavailability data of this substance 
is scarce in the literature, especially using urine excretion 
data. 
The bioavailability study of the cephalexin using 
human urine shows that A and B products can be 
considered bioequivalents and, therefore, interchangeable.
Based on this study, the methodology can be 
applied to other drugs that are excreted unchanged. For 
new compounds, the permeability characterization can 
be a previous test before bioequivalence/bioavailability 
studies and then, complemented with studies using urinary 
excretion data to predict the absorption of a drug. 
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